51-week clinical study compared Sandoz Proposed biosimilaradalimumab with reference medicine Humira®* in patients with moderate-to-severe psoriasis1 Sandoz proposed biosimilaradalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases Sandoz is leading the way in addressing challenges around access to treatment for people living with immunological diseases Sandoz, a […]
This post first appeared on Global Banking And Finance Review Magazine – Fin, please read the originial post: here
